Regulatory Immunotherapy in Bone Marrow Transplantation

Table 1

Murine models of immunoregulatory cells in hematopoietic cell transplantation.

Immunoregulatory cell	Reference	Model	Contributions
Natural killer T (NKT) Cells	Lan et al. [17]	MHC-mismatched; C57BL/6→BALB/c	(i) TLI and ATS regimen increases recipient NK1.1^+TCRαβ ^+ cells.; (ii) Recipient NKT cells mediate GVHD protection.
	Hashimoto et al. [18]	MHC-mismatched; BALB/c→C57BL/6	(i) α-Gal-Cer treatment of recipients.; (ii) Recipient NKT cells mediate GVHD protection via IL-4.
	Pillai et al. [19]	MHC-mismatched; C57BL/6→BALB/c	(i) TLI/ATS regimen.; (ii) Recipient NKT cells regulate GVHD without inhibiting GVT.
	Leveson-Gower et al. [20]	MHC-mismatched; C57BL/6→BALB/c	(i) Donor NKT cells regulate GVHD without inhibiting GVT, via IL-4.
Regulatory T cells (Treg)	Taylor et al. [54]	Ex vivo allo-MLR:	(i) Tolerance is dependent on presence of CD4^+CD25^+ T cell fraction.
	Hoffmann et al. [55]	MHC-mismatched; C57BL/6→BALB/c	(i) Donor Treg protects against lethal GVHD induced by donor cells through IL-10 production.
	Edinger et at. [56]	MHC-mismatched; C57BL/6→BALB/c	(i) Donor Treg GVHD protection does not alter GVT.
NKT-Treg interaction	Pillai et al. [21]	MHC-mismatched; C57BL/6→BALB/c	(i) TLI/ATS regimen.; (ii) Recipient iNKT induces donor Treg proliferation to suppress GVHD.

MHC: mouse major histocompatibility complex; TLI: total lymphoid irradiation; ATS: rabbit antimouse thymocyte serum; α-Galcer: α-galactosylceramide (NKT-specific glycolipid ligand); IL-4: interleukin 4; IL-10: interleukin 10.